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Abstract
Itch is a difficult to treat symptom that may accompany neoplastic disease. At least some of the itch
symptoms are due to abnormal endogenous opioid synthesis in the liver. In the past opioid receptor
antagonists were found useful to treat itch in such patients. However, their use is limited by the abstinence
symptoms experienced by the patient. Another approach would be to use an opioid with high affinity and
slow dissociation from the receptor not to allow endogenous opioids to interact with the opioid receptors.
In this paper we describe a patient with severe itch due to hepatocellular cancer who responded to the
treatment with buprenorphine.
Key words: buprenorphine, pruritus, hepatogenic itch
Address for corresponence: Ma‡gorzata Krajnik
Chair of Palliative Care, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland
e-mail: malgorzata.krajnik@wp.pl
Advances in Palliative Medicine 2007, 6, 8386
Copyright ' 2007 Via Medica, ISSN 18983863
Introduction
Pruritus is a rare but difficult symptom to treat in
the course of neoplastic disease. This symptom does
not usually respond adequately to antihistamines
[1]. Antihistamines may provide some benefit by
virtue of their sedative properties; an effect similar
to sedation by benzodiazepines [2]. Recently, new
ideas have been launched suggesting that pruritus
in liver diseases may be due to the abnormal pro-
duction of opioids by the sick liver [3]. Opioid recep-
tor antagonists naloxone and naltrexone have both
been tried with success. However, these drugs may
cause a very unpleasant opioid withdrawal-like re-
action [4] and may with time become hepatotoxic.
In order to treat pruritus, opioids with different pro-
files were tried. It was suggested that mu-agonistic
opioids are pro-pruritic, while kappa-agonistic opi-
oids are anti-pruritic [5]. Nalmefene, another opioid
antagonist with a slightly different pharmacological
profile, showed promising results in the treatment
of this type of itch [6]. Buprenorphine is a partial
opioid agonist of mu opioids receptors. It has an
extremely high affinity to mu opioid receptors, whilst
stimulating them only weakly. Hypothetically, bu-
prenorphine, with its high affinity and slow dissoci-
ation from opioid receptors, may successfully com-
pete with the binding sites, protecting them from
interaction with endogenous opioids. A controlled
trial with sublingual buprenorphine on 5 patients
with pruritis of cholestasis [7] indicated that some
patients may respond well to this treatment. How-
ever, the trial was prematurely discontinued because
of the high toxicity of buprenorphine. Two authors
of this article (Zbigniew Zylicz and Ma‡gorzata Kra-
jnik) had previously tried buprenorphine sublingual
tablets in one patient and found the therapy to be
effective and worthy of reconsideration [8]. When
buprenorphine patches (Transtecfi) were licensed for
use as analgesics in Poland, we decided to try them
in a patient with severe intractable itch due to hepa-
tocellular carcinoma. A similar approach was suc-
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cessful in at least one other patient with itch due to
primary biliary cirrhosis [9].
Case description
The patient was a 61-year-old man diagnosed
eight weeks earlier with advanced hepatocellular
cancer. For several years previously he had been
treated for heart failure, diabetes mellitus and gout.
Initially, he was admitted to the Cardiology Depart-
ment because of his unexplained deterioration and
exacerbation of breathlessness. During his assess-
ment he was diagnosed with liver metastases and
transferred to the Oncology Centre. The diagnosis
of advanced hepatocellular cancer was confirmed
by a biopsy but due to his poor general condition no
oncological treatment was offered. At the time of
his referral for home palliative care he was suffering
from severe generalized itch of 9/10 intensity (ac-
cording to the Numerical Rating Scale (NRS), where
0 means no itch at all and 10 is the worst imagin-
able itch), which left him unable to sleep and ex-
hausted. He complained of occasional breathless-
ness, a painful oedematous left leg, abdominal pain,
constipation, fatigue and low mood. The alkaline
phosphatase was 724.03 U/l (normal values: 35
129 U/l) while bilirubin was normal (15.43 umol/l).
Two weeks earlier, 5 mg of morphine every 4 hours
had apparently been introduced for the treatment
of pain and dyspnoea, together with fractionated
heparine for suspected but not confirmed throm-
botic complications. There was also an extensive list
of medications which he had been taking for many
years (insulin, glimepiride and metformin, allopu-
rinol, amlodipine, thiazide, irbesartan and panto-
prazole). All of these medications were continued at
the time of his referral.
During the first home palliative care visit, the
patient presented with considerable hepatomegaly,
an extended abdomen and dry skin. Despite an ap-
parent lack of jaundice, we hypothesized that
cholestasis might be the most probable cause of
pruritus. Regular morphine was changed to trans-
dermal buprenorphine (Transtec 35 ug/h) with 5 mg
oral morphine offered as a rescue dose in case of
pain or dyspnoea. Apart from docusate sodium, a
short trial of dexamethasone was prescribed. A re-
gime for skin treatment was implemented, based
on tea tree preparations. The intensity of the itch
decreased after 2 days to 01/10. The patient occa-
sionally complained of a localized itch on the upper
and lower extremities, which could be effectively
relieved by local measures. The patient deteriorated
further and jaundice became clinically apparent. The
main problem was back pain, which was satisfacto-
rily controlled by the increase of the buprenorphine
dose to 52.5 ug/h and the addition of paracetamol
1 g as needed (up to 3 times a day). The patient only
used the breakthrough medication occasionally.
Apart from the small dose of insulin, the other pre-
viously prescribed drugs were gradually discontin-
ued. The dose of buprenorphine continued for 3
weeks until the patients death. However, in the 3
days prior to death, morphine (20 mg/24 h), hyoscine
butylbromide (40 mg/24 h) and haloperidol (up to 10
mg/24 h) were administered by SC syringe driver and
provided satisfactory control of dyspnoea exacerba-
tion, death rattle and restlessness. The patient re-
mained free of itch and died peacefully at home.
Discussion
Buprenorphine, when appropriately titrated, may
be helpful in the treatment of the itch accompany-
ing primary biliary cirrhosis [9] and hepatocellular
cancer (as in this case). The drug is highly lipophylic
and shows a high degree of protein binding (96%),
mainly to alpha and beta globulins, and its metabo-
lism is dependent on the activity of liver enzymes
[10]. The plasma half-life of buprenorphine may be
very long (2030 hours) and one should expect to
achieve a steady state in 79 days. Buprenorphine
may induce drowsiness and other opioids-related
adverse effects. The dose should be carefully titrat-
ed and the time of titrations should not be too
short. Exogenous morphine administered 2 weeks
before referral to palliative care for pain and dysp-
noea could be, at least potentially, the trigger for
the onset of itch. However, later in the treatment of
this patient, morphine was successfully used together
with buprenorphine and helped to control symp-
toms. We did not have the impression that it coun-
teracted the effects of buprenorphine. In a patient
with rapidly developing hepatic insufficiency, it is
important to discontinue all other drugs that may
overload the hepatic oxygenase systems. This too
may contribute to a better control of itch.
We conclude that carefully titrated transdermal
buprenorphine should be further investigated as a
potential antipruritic agent.
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